vimarsana.com

Latest Breaking News On - Rare disease designation - Page 1 : vimarsana.com

PANTHERx® Rare Pharmacy Wins Sixth Patient Choice Award

/PRNewswire/ For a sixth time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™. Since.

United statesRichard farisRob snyderInsights technologyZitter insights specialty pharmacy patient satisfactionManaged markets insightsPatient choice awardChoice awardRare chief executive officer robRare disease designationRare disease distinctionPantherx rare pharmacy

Team Arnav Foundation Partners with OS Therapies Supporting the Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ OS Therapies, a research and clinical-stage biopharmaceutical company and Team Arnav Foundation, a non-profit 501c3 organization focused on.

Paul romnessDhruv krishnaTeam arnav foundationFounder of team arnav foundationTeam arnavOs therapies incArnav foundationClinical trialResected osteosarcomaPediatric osteosarcoma cancerOverall survivalRare disease designationOrphan designationsBreak through designationOs therapies

U S FDA approves first treatment option for generalized pustular psoriasis flares in adults

Press release content from Business Wire. The AP news staff was not involved in its creation.

New yorkUnited statesRheinland pfalzPetra kienleCarinne brouillonMark lebwohlEricj waldman department of dermatologyIcahn school of medicine at mount sinaiCorporate communicationsDrug administrationEuropean medicines agencyBoehringer ingelheimClinical therapeuticsIcahn schoolMount sinaiManaging directors

Boehringer Ingelheim receives FDA approval for GPP flares therapy

Boehringer Ingelheim has received the US FDA approval for its spesolimab, to treat adult patients with generalized pustular psoriasis (GPP) flares.

Carinne brouillonIngelheim managing directorsOrphan drug designationPriority reviewRare disease designationBreakthrough therapy designation

Boehringer Ingelheim: U S FDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares After

New yorkUnited statesPetra kienleCarinne brouillonMark lebwohlEricj waldman department of dermatologyIcahn school of medicine at mount sinaiCorporate communicationsEuropean medicines agencyBoehringer ingelheimDrug administrationClinical therapeuticsIcahn schoolMount sinaiManaging directorsHuman pharma

vimarsana © 2020. All Rights Reserved.